Radiopharm Theranostics Full Year 2025 Earnings: Beats Expectations

Radiopharm Theranostics (ASX:RAD) Full Year 2025 Results

Key Financial Results

• Net loss: AU$38.3m (loss narrowed by 20% from FY 2024).
• AU$0.018 loss per share (improved from AU$0.12 loss in FY 2024).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

RAD Products In Clinical Trials

• Phase III: 3.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Radiopharm Theranostics Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 75%. Earnings per share (EPS) also surpassed analyst estimates by 17%.

Looking ahead, revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Biotechs industry in Australia.

Performance of the Australian Biotechs industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 3 warning signs for Radiopharm Theranostics you should be aware of, and 1 of them is potentially serious.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.